Antiviral Therapy for Adults With Chronic Hepatitis B: A Systematic Review for a National Institutes of Health Consensus Development Conference

  1. Tatyana A. Shamliyan, MD, MS;
  2. Roderick MacDonald, MS;
  3. Aasma Shaukat, MD, MPH;
  4. Brent C. Taylor, PhD, MPH;
  5. Jian-Min Yuan, MD, PhD;
  6. James R. Johnson, MD;
  7. James Tacklind, BS;
  8. Indulis Rutks, BS;
  9. Robert L. Kane, MD; and
  10. Timothy J. Wilt, MD, MPH
  1. From the Minnesota Evidence-based Practice Center, University of Minnesota School of Public Health, Minneapolis Veterans Affairs Center for Chronic Disease Outcomes Research, and the University of Minnesota Medical School, Minneapolis, Minnesota.
    1. Figure.
      View larger version:
        Figure. Absolute rates of the frequent (>40%) adverse effects after interferon therapy, by baseline HBeAg status.

        HBeAg = hepatitis B e antigen.

      Responses to this article

      • Hepatitis B Treatment Improves Clinical Outcomes
        • Anna SF Lok and
        • Marc G. Ghany, Norah A. Terrault, W. Ray Kim, Marion Peters, Jules L. Dienstag
        Ann Intern Med published online October 26, 2009
      « Previous | Next Article »Table of Contents

      This Article

      1. Ann Intern Med January 20, 2009 vol. 150 no. 2 111-124
      1. AbstractFREE
      2. » Figures
      3. Full Text
      4. Full Text (PDF)
      5. Appendix Tables

      Current Issue

      1. November 17, 2009, 151 (10)
      1. Alert me to current issues